Trevi Therapeutics, Inc. TRVI Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s payments of stock issuance costs?
- Trevi Therapeutics, Inc. (TRVI) reported payments of stock issuance costs of $0 in Q4 2025.
- What is the long-term trend for Trevi Therapeutics, Inc.'s payments of stock issuance costs?
- Over 3 years (2021 to 2025), Trevi Therapeutics, Inc.'s payments of stock issuance costs has grown at a 24.4% compound annual growth rate (CAGR), from $420K to $809K.
- What does payments of stock issuance costs mean?
- Reflects the direct costs incurred in connection with the issuance of equity securities, including legal, accounting, and underwriting fees. Monitoring these costs is important for evaluating the efficiency of the company's capital-raising activities.